Phase II trial of sunitinib in patients with relapsed or refractory germ cell tumors

By Feldman Darren   Turkula Stefan   Ginsberg Michelle   Ishill Nicole   Patil Sujata   Carousso Maryann   Bosl George   Motzer Robert  

Investigational New Drugs, Vol. 28, Iss. 4, 2010-08 ,pp. : 523-528

Springer Publishing Company

Access to resources Recommend Favorite

Combined treatment with gemcitabine plus oxaliplatin shows encouraging efficacy in patients with relapsed or cisplatin-refractory germ cell tumours

By  

Inpharma, Vol. 1, Iss. 1430, 2004-01 ,pp. : 13-13

Adis International

Access to resources Recommend Favorite

Phase 1 trial of Anvirzel™ in patients with refractory solid tumors

By Mekhail Tarek   Kaur Hanspreet   Ganapathi Ram   Budd G.   Elson Paul   Bukowski Ronald  

Investigational New Drugs, Vol. 24, Iss. 5, 2006-09 ,pp. : 423-427

Springer Publishing Company

Access to resources Recommend Favorite

Phase I study of 17-allylamino-17 demethoxygeldanamycin, gemcitabine and/or cisplatin in patients with refractory solid tumors

By Hubbard Joleen   Erlichman Charles   Toft David   Qin Rui   Stensgard Bridget   Felten Sara   Ten Eyck Cynthia   Batzel Gretchen   Ivy S.   Haluska Paul  

Investigational New Drugs, Vol. 29, Iss. 3, 2011-06 ,pp. : 473-480

Springer Publishing Company

Access to resources Recommend Favorite

Phase II trial of imatinib (Gleevec®) in patients with metastatic renal cell carcinoma

By Vuky Jacqueline   Isacson Christina   Fotoohi Mehran   Cruz Jason   Otero Henry   Picozzi Vincent   Malpass Thomas   Aboulafia David   Jacobs Andrew  

Investigational New Drugs, Vol. 24, Iss. 1, 2006-01 ,pp. : 85-88

Springer Publishing Company

Access to resources Recommend Favorite